This work introduces a biopsy-independent detection scheme for MYCN amplification, which holds promise for broad deployment in precision medicine and routine diagnostics.
Abstract
MYCN gene copy number in neuroblastoma tissue sections is a well-established prognostic parameter used to guide clinical risk stratification. Nevertheless, the majority of neuroblastoma cases are identified at late stages, when tumors are bulky and unresectable, precluding safe tissue sampling through surgery or core biopsy and thereby compromising the accuracy of molecular risk assessment. To address this critical diagnostic challenge, we have developed a nonbiopsy fluorescent signal conversion strategy capable of detecting MYCN amplification status without relying on tissue biopsies. The core of this method is a DNA-based biosensor based on cascade cyclic amplification (CCA), which undergoes conformational activation upon specific hybridization with intracellular MYCN or NAGK mRNA, releasing tunable fluorescent signals. The normalized fluorescence intensity ratio (referred to as the M/N ratio) quantitatively reflects the MYCN copy number status. This CCA system integrates two orthogonal functional modules-MYCN-CCA and NAGK-CCA-both exploiting elevated cytoplasmic APE1 activity in pathologically altered neuroblastoma cells as a tumor-specific molecular switch and endogenous enzymatic amplifier. APE1-mediated interactions trigger structural changes that drive the dissociation of fluorophore from quencher, generating stable and quantifiable fluorescent signals. Analytical validation demonstrates exceptional sensitivity, with detection limits of 0.52 aM for MYCN mRNA and 0.65 aM for NAGK mRNA. Importantly, the CCA platform enables precise quantification of the M/N ratio in both cell line-derived and patient-derived xenograft models, and allows rapid in situ evaluation in frozen sections of clinical neuroblastoma samples. Collectively, this work introduces a biopsy-independent detection scheme for MYCN amplification, which holds promise for broad deployment in precision medicine and routine diagnostics.
Sensitive detection of minimal residual disease (MRD) remains a major unmet need in high-risk neuroblastoma. MYCN amplification, a hallmark of high-risk disease, typically occurs on extrachromosomal DNA (ecDNA), but the potential of ecDNA-associated genomic rearrangements for individualized MRD monitoring has not been...
A. Szymansky, F. Hertwig, A. Winkler et al.· bioRxiv· 0 citations
Circulating tumour DNA (ctDNA) in blood is now used in a less invasive way to guide personalised cancer therapy. Several blood tests can be conducted on ctDNA to determine whether there is a distant spread of cancer cells, discover microscopic cancer cells remaining after surgery, and observe how the immune system resp...
Ya-Nan Chen· Theoretical and Natural Scie...· 0 citations
Multiple myeloma (MM) progression and therapeutic resistance are dictated by the bone marrow microenvironment (BMME). Conventional single-marker immunohistochemistry (IHC) cannot resolve the complex cellular neighborhoods, non-cellular signaling networks, and spatial exclusion patterns that characterize this disease. M...
Di Zhou, Xiang-Yi Guo, Chen-Chen Wang et al.· Frontiers in Oncology· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with an unmet need for novel precision based therapies. While KRAS canonically drives tumor progression, MYC amplification has emerged as a critical downstream resistance mechanism. Efforts have been made to elucidate the role of MYC amplification in PDAC...
Audrey G. Sawyer, Lauryn E. Flannagan, Paulina N. Esguerra et al.· Cancer Research· 0 citations
Circulating cell-free DNA (cfDNA) and its tumor-derived fraction, circulating tumor DNA (ctDNA), enable non-invasive tumor genotyping, longitudinal disease monitoring, and molecular residual disease (MRD) assessment. Classical Hodgkin lymphoma (cHL) is particularly suitable for ctDNA-based analysis because malignant Ho...
M. Bednarek, Maria Komossa, Joanna Bidzińska· Frontiers in Oncology· 0 citations
Microsatellite-stable (MSS) colorectal cancer (CRC) is a molecularly complex and clinically challenging disease subtype, lacking effective targeted therapies. Leveraging multiomic data from ∼2,000 tumor samples (including 316MSS CRCs not previously profiled) representing ∼4,500 molecular profiles and 195,246 single cel...
A. Sadanandam, A. O'Farrell, I. Miller et al.· Cancer Cell· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.